- Chris Froome's urine test showed double permitted amount of Salbutamol
- British star will provide whatever information is required by UCI over medication
- Team Sky say doctor upped dose due to 'acute asthma symptoms during race
- Froome said: 'With the team, I will provide whatever information UCI requires'
Published: 02:33 EST, 13 December 2017 | Updated: 02:34 EST, 13 December 2017
Chris Froome will provide whatever information is required by UCI about his use of medication for asthma during the 2017 Vuelta a Espana.
A urine test revealed a concentration of Salbutamol double the WADA threshold, Team Sky have said in a statement.
Team Sky say Froome experienced 'acute asthma symptoms' during the final week of the Vuelta and increased his dosage of Salbutamol on the advice of the Team Sky doctor.
Chris Froome's urine test from the Vuelta a Espana double the allowed dose of Salbutamol
The British rider claimed victory in the Grand Tour to complete a remarkable year
The four-time Tour de France winner conducted a urine test on September 7 which revealed a concentration of Salbutamol of 2,000 nanograms, twice the WADA threshold of 1,000.
The Team Sky statement said the 'use of permissible dosages of Salbutamol can sometimes result in elevated urinary concentrations, which require explanation'.
Froome said: 'The UCI is absolutely right to examine test results and, together with the team, I will provide whatever information it requires.'
The four-time Tour de France champion's test was taken on September 7 in Spain
The post Chris Froome to cooperate after Vuelta a Espana drug test appeared first on News Wire Now.